ERBB2 and breast cancer: An Open‐Label, Single‐Arm, Phase II Study of Pertuzumab With High‐Dose Trastuzumab for the Treatment of Central Nervous System Progression Post‐Radiotherapy in Patients With HER2‐Positive Metastatic Breast Cancer (PATRICIA)